Inhaled chemotherapeutics may enhance pulmonary drug exposure to malignant lesions in the lung without substantially contributing to systemic toxicities. The … Continued

Suspensions of submicron particle taxanes (Figure 1) allow for direct administration of high, sustained levels of chemotherapeutics at the site … Continued

NanOlogy may offer an alternative treatment option for patients with bladder cancer Investigational drug, NanoDoce, is injected locally into tumor … Continued

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* … Continued

The combination of chemotherapies and immunotherapies highlights the significance of small molecule drug development as an ongoing treatment modality. Although … Continued

FOR IMMEDIATE RELEASEOctober 24, 2018 CritiTech Particle Engineering Solutions Presents at BARDA Industry Day 2019 CritiTech Particle Engineering Solutions was … Continued

FOR IMMEDIATE RELEASEMay 30, 2018 LAWRENCE, KS – CritiTech Particle Engineering Solutions, a growing Contract Development Manufacturing Organization (CDMO) and … Continued

Update – 6/4/18:  Link to NanOlogy Poster presented at 2018 ASCO Annual Meeting Studies of Inhaled NanoPac Show Prolonged Retention … Continued

FORT WORTH, Texas—Researchers have been trying to develop therapeutic agents powerful enough to destroy tumors without harmful effects to healthy … Continued

OCTOBER 16, 2017 BY SARAH FAULKNER In the last two weeks, NanOlogy has launched trials evaluating its cancer-fighting paclitaxel nanoparticle suspension in patients with … Continued